First Bellwether Trial in Roundup MDL Reaches End of Initial Science-Heavy Phase
A San Francisco federal jury is considering whether Monsanto's Roundup weedkiller was a significant factor contributing to Edwin Hardeman's cancer diagnosis.
March 12, 2019 at 04:30 PM
5 minute read
The original version of this story was published on The Recorder
A lawyer representing a Northern California man who claims that exposure to Monsanto Co.'s Roundup weedkiller caused him to develop cancer urged a San Francisco jury to consider the amount and duration of his exposure.
Aimee Wagstaff of Andrus Wagstaff on Tuesday pointed to expert testimony that concluded that her client Edwin Hardeman sprayed about 6,000 gallons of Roundup on his property over a 26-year span. Monsanto's experts, she argued, didn't consider the amount her client sprayed or the duration of his exposure when they concluded that Roundup wasn't a significant factor contributing to his cancer.
“The dose makes the poison,” Wagstaff repeated during closing arguments Tuesday in the first bellwether trial in the multidistrict Roundup litigation pending before U.S. District Judge Vince Chhabria of the Northern District of California.
Chhabria bifurcated the trial to frontload the question of whether or not Monsanto's Roundup herbicide was a significant cause of plaintiff Hardeman's non-Hodgkins lymphoma. If the jury unanimously finds that a preponderance of the evidence shows that Roundup was a significant factor contributing to Hardeman's cancer, the case will move onto a second phase to consider what Monsanto knew, how the company conducted itself, and potential damages. A finding that Roundup was not a significant factor would be a victory for the defense and the end of the first bellwether trial, but not the MDL. If the six-member jury is unable to reach a unanimous verdict, the result would be a mistrial, and Hardeman's case could be tried again.
Closing arguments Tuesday went significantly smoother for Wagstaff than the opening of trial did. Chhabria interrupted Wagstaff's opening repeatedly and later sanctioned her $500 for what he called “obvious violations” of his pretrial orders during her opening presentation. The judge also ordered Wagstaff to hand over a list of every other attorney who worked on the opening within two weeks of the end of Hardeman's trial for additional possible sanctions.
The stakes are significant for Monsanto's parent company Bayer AG, which last year was hit with a $289 million verdict in San Francisco Superior Court in a Roundup case outside the MDL proceedings. The state court judge overseeing that case, however, slashed the award by more than $200 million.
Pretrial and away from the jury, Chhabria has expressed skepticism about the strength of plaintiffs' scientific evidence. In July, he narrowly allowed plaintiffs' cases in the MDL to move forward, but called evidence that glyphosate—the active ingredient in Roundup—causes non-Hodgkin's lymphoma “shaky” but “admissible.” He wrote that plaintiffs had a “daunting challenge” to prove causation.
Aside from the trial structure, Hardeman's case has some significant differences from the state court trial that yielded the blockbuster verdict. The plaintiff in the state case, Dewayne “Lee” Johnson, was diagnosed with non-Hodgkin's lymphoma, or NHL, after spraying a Monsanto herbicide as part of his job as a school groundskeeper. Johnson's case was fast-tracked for trial because of his dire prognosis. Hardeman, by contrast, is in remission from cancer and developed NHL after using Roundup on his own property to clear poison oak and weeds from hiking trails and his driveway. He also had Hepatitis for decades, something that Monsanto's lawyers argued was a significant risk factor for him contracting NHL.
But in her closings, Wagstaff pointed out that Hardeman's Hepatitis never resurfaced throughout his six rounds of chemotherapy to treat his cancer. “Not one time did the Hep C ever show up,” she said. “So where are the facts of this Hep C swimming around at undetectable level? They're just not there.”
Brian Stekloff, a lawyer at Wilkinson Walsh + Eskovitz who is representing Monsanto in the Hardeman trial, pointed out that the plaintiff's treating physicians had never asked about his Roundup use or tied it to his diagnosis.
“Roundup did not factor into their treatment, whatsoever,” he said. He also said that the Hardeman's lawyers were falsely trying to make the case an issue of “Roundup versus Hepatitis C.” In reality, he argued, that Hardeman's causation expert had testified that Roundup was the primary factor driving his cancer.
“The case they have presented to you is that it is Roundup and Roundup only,” he said “No one has come into this courtroom and said it could have been both.”
Stekloff further argued that the largest human study to look at whether use of the active ingredient in Roundup caused cancer—a long-term study of agricultural workers called the Agricultural Health Study—found that levels of NHL among those exposed were similar to those in the general population—about 1 percent in both. Stekloff said that “if what they're saying is true if Roundup is this huge problem that is causing cancer everywhere” you would expect to see a spike in NHL cases in the wake of the exponential increase of Roundup use since the 1990s.
The number of cases, he said, has remained steady.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All'Ill-Gotten Gains'?: Cadwalader Alleges Beef Price-Fixing Conspiracy Hurts McDonald's
2 minute read'Climate-Smart Beef'?: DC Lawsuit Accuses Tyson Foods of False Advertising
3 minute readMonsanto Scores 2nd Phila. Roundup Verdict, but Fails to Stop Impending Trial
3 minute read'Anticompetitive Scheme?': Tyson Foods Faces Missouri Antitrust Class Action in Chicken Plant Dispute
3 minute readTrending Stories
Who Got The Work
Dechert partners Andrew J. Levander, Angela M. Liu and Neil A. Steiner have stepped in to defend Arbor Realty Trust and certain executives in a pending securities class action. The complaint, filed July 31 in New York Eastern District Court by Levi & Korsinsky, contends that the defendants concealed a 'toxic' mobile home portfolio, vastly overstated collateral in regards to the company's loans and failed to disclose an investigation of the company by the FBI. The case, assigned to U.S. District Judge Pamela K. Chen, is 1:24-cv-05347, Martin v. Arbor Realty Trust, Inc. et al.
Who Got The Work
Arthur G. Jakoby, Ryan Feeney and Maxim M.L. Nowak from Herrick Feinstein have stepped in to defend Charles Dilluvio and Seacor Capital in a pending securities lawsuit. The complaint, filed Sept. 30 in New York Southern District Court by the Securities and Exchange Commission, accuses the defendants of using consulting agreements, attorney opinion letters and other mechanisms to skirt regulations limiting stock sales by affiliate companies and allowing the defendants to unlawfully profit from sales of Enzolytics stock. The case, assigned to U.S. District Judge Andrew L. Carter Jr., is 1:24-cv-07362, Securities and Exchange Commission v. Zhabilov et al.
Who Got The Work
Clark Hill members Vincent Roskovensky and Kevin B. Watson have entered appearances for Architectural Steel and Associated Products in a pending environmental lawsuit. The complaint, filed Aug. 27 in Pennsylvania Eastern District Court by Brodsky & Smith on behalf of Hung Trinh, accuses the defendant of discharging polluted stormwater from its steel facility without a permit in violation of the Clean Water Act. The case, assigned to U.S. District Judge Gerald J. Pappert, is 2:24-cv-04490, Trinh v. Architectural Steel And Associated Products, Inc.
Who Got The Work
Michael R. Yellin of Cole Schotz has entered an appearance for S2 d/b/a the Shoe Surgeon, Dominic Chambrone a/k/a Dominic Ciambrone and other defendants in a pending trademark infringement lawsuit. The case, filed July 15 in New York Southern District Court by DLA Piper on behalf of Nike, seeks to enjoin Ciambrone and the other defendants in their attempts to build an 'entire multifaceted' retail empire through their unauthorized use of Nike’s trademark rights. The case, assigned to U.S. District Judge Naomi Reice Buchwald, is 1:24-cv-05307, Nike Inc. v. S2, Inc. et al.
Who Got The Work
Sullivan & Cromwell partner Adam S. Paris has entered an appearance for Orthofix Medical in a pending securities class action arising from a proposed acquisition of SeaSpine by Orthofix. The suit, filed Sept. 6 in California Southern District Court, by Girard Sharp and the Hall Firm, contends that the offering materials and related oral communications contained untrue statements of material fact. According to the complaint, the defendants made a series of misrepresentations about Orthofix’s disclosure controls and internal controls over financial reporting and ethical compliance. The case, assigned to U.S. District Judge Linda Lopez, is 3:24-cv-01593, O'Hara v. Orthofix Medical Inc. et al.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250